Analysis of the efficacy of saccharomyces boulardii combined with ursodeoxycholic acid and blue light phototherapy in treating cholestasis in neonates aged 35 weeks and above

Abstract

Abstract: Objective To investigate the clinical efficacy of Saccharomyces boulardii in combination with ursodeoxycholic acid and blue light phototherapy on neonatal intrahepatic cholestasis in infants aged ≥35 weeks. Methods From January 2021 to January 2024, 92 infants with intrahepatic cholestasis aged ≥35 weeks were recruited at Xingyuan Hospital in Yulin City. Using a random number table method, they were divided into a reference group (n=46, treated with ursodeoxycholic acid and blue light phototherapy) and a Saccharomyces boulardii group (n=46, treated with the reference group's regimen plus Saccharomyces boulardii). Clinical efficacy, liver function markers, intestinal flora distribution, inflammation levels, liver and spleen size, and jaundice index were compared between the two groups before and after treatment. Results After treatment, the total effectiveness rate in the Saccharomyces boulardii group reached 89.13% (41/46), which was significantly higher than 71.74% (33/46) in the reference group (P<0.05). Post-treatment, the Saccharomyces boulardii group showed lower levels of TBil (81.20±17.13) μmol/L, DBil (65.42±12.44) μmol/L, and TBA (75.19±16.88) U/L compared to the reference group's TBil (91.88±18.69) μmol/L, DBil (73.88±13.59) μmol/L, and TBA (88.09±24.10) U/L (P<0.05). The levels of bifidobacteria (8.64±0.63) lg CFU/g and lactobacilli (8.75±0.66) lg CFU/g were higher, while levels of E. coli (6.37±0.58) lg CFU/g were lower compared to the reference group (P<0.05). Additionally, the Saccharomyces boulardii group exhibited lower hs-CRP (0.57±0.22) mg/L, IL-6 (32.17±4.92) ng/L, and TNF-α (214.27±31.82) ng/L levels than the reference group (P<0.05). Liver span (2.39±0.37) cm, spleen span (0.67±0.10) cm, and jaundice indices (11.12±4.96) mg/dL were also significantly lower than those in the reference group (P<0.05). Conclusion The combination of saccharomyces boulardii, ursodeoxycholic acid, and blue light phototherapy significantly enhances liver function, optimizes intestinal flora, and reduces inflammation in neonates aged 35 weeks and above, suggesting its potential for expanded clinical use.

Key words: Intrahepatic cholestasis, Saccharomyces boulardii, Ursodeoxycholic acid, Blue light phototherapy, Neonate

CHANG Ya-na, JIA Yang. Analysis of the efficacy of saccharomyces boulardii combined with ursodeoxycholic acid and blue light phototherapy in treating cholestasis in neonates aged 35 weeks and above[J]. Chinese Hepatolgy, 2025, 30(10): 1414-1418.

References

[1] 罗欣,成鹏,陆茵,等. 丁香酸调控胆汁酸代谢和肠道屏障改善胆汁淤积肝病的研究[J]. 南京中医药大学学报,2024,40(4):350-358.
[2] 曾丽娟,姚芳,孙金龙,等. 血清脂联素在早产儿胃肠外营养相关性胆汁淤积中的预测价值[J]. 中国医师杂志,2023,25(12):1820-1823.
[3] Nsengimana B, Okpara E S, Hou W, et al. Involvement of oxidative species in cyclosporine-mediated cholestasis[J]. Front Pharmacol, 2022, 13: 1004844.
[4] 叶圣,郑丽珠. 布拉酵母菌在新生儿肠外营养相关性胆汁淤积中的治疗效果[J]. 吉林医学,2022,43(5):1260-1262.
[5] Uchida Y, Takahashi Y, Morimoto Y, et al. Noninvasive monitoring of bilirubin photoisomer excretion during phototherapy[J]. Sci Rep, 2022, 12(1): 11798.
[6] 中华医学会肝病学分会,中华医学会消化病学分会,中华医学会感染病学分会. 胆汁淤积性肝病诊断和治疗共识(2015)[J]. 实用肝脏病杂志,2016,19(6):771-781.
[7] 李涛,程旸,买斯吐热·尼加提. 复方甘草酸苷联合微生态制剂对胆汁淤积性肝病婴儿肠道菌群及血清TGF-β1、IL-6的影响[J]. 中西医结合肝病杂志,2022,32(2):131-134,149.
[8] Teng J, Wickman L, Reilly M, et al. Population-based incidence and risk factors for cholestasis in hemolytic disease of the fetus and newborn[J]. J Perinatol, 2022, 42(6): 702-707.
[9] Watchko J F, Maisels M J. Management of severe hyperbilirubinemia in the cholestatic neonate: a review and an approach[J]. J Perinatol, 2022, 42(6): 695-701.
[10] 姚嘉明,陈芝芸,陈曦,等. ANIT诱导亚急性肝内胆汁淤积大鼠模型肝脏氧化应激水平及胆汁酸受体表达的变化[J]. 浙江临床医学,2023,25(1):15-17,21.
[11] Hargett S, Lahiri S, Kowalski G M, et al. Bile acids mediate fructose-associated liver tumour growth in mice[J]. Biochim Biophys Acta Mol Basis Dis, 2024, 1870(3): 167029.
[12] D′Antongiovanni V, Antonioli L, Benvenuti L, et al. Use of saccharomyces boulardii CNCM I-745 as therapeutic strategy for prevention of nonsteroidal anti‐inflammatory drug‐induced intestinal injury[J]. Br J Pharmacol, 2023, 180(24): 3215-3233.
[13] 周保仓,曹亚伟,刘泉,等. 肝爽颗粒联合熊去氧胆酸治疗原发性胆汁性胆管炎疗效观察[J]. 辽宁中医杂志,2024,51(5):135-138.
[14] Zhang Y, Lu B, Dong Y, et al. Saccharomyces boulardii combined with triple therapy alter the microbiota in the eradication of helicobacter pylori infection[J]. Sci Rep, 2024, 14(1): 13152.
[15] Anne R P, Kadyada S P, Aradhya A S, et al. Ursodeoxycholic acid for preventing parenteral nutrition-associated cholestasis in neonates: a systematic review and meta-analysis[J]. Fundam Clin Pharmacol, 2024.
[16] 冯慧玲,冯孝强,李帆,等. 低剂量维生素D辅助蓝光治疗新生儿黄疸的单中心随机对照研究[J]. 中国妇幼健康研究,2023,34(4):74-79.
[17] 刘静文,任海霞,袁方婷,等. 布拉氏酵母菌在消化系统疾病中的研究进展[J]. 医学综述,2022,28(3):449-455.
[18] 李艳芬,张晓文,王艳茹,等. 应用奥贝胆酸和贝特类药物治疗对熊去氧胆酸治疗不完全应答的原发性胆汁性胆管炎患者临床研究[J]. 实用肝脏病杂志,2023,26(2):226-229.
[19] Perkov S, Gorin D. Noninvasive, continuous fluorescence monitoring of bilirubin photodegradation[J]. Phys Chem Chem Phys, 2023, 25(6): 4460-4466.
[20] 刘希,廖杉,刘小乖. 熊去氧胆酸治疗胆汁淤积性肝病患儿的临床疗效及对血清炎症指标及肠道菌群的影响[J]. 肝脏,2022,27(6):703-707.